Kingsley Taft is a senior partner and national co-chair of Goodwin's Life Sciences practice and member of the Allocations Committee. He represents emerging to mature life sciences companies in all aspects of their business and legal affairs, including company formation, venture financings, strategic alliances, M&A, IPOs and other capital market transactions, and other financing and commercial transactions. Mr. Taft has extensive experience in assisting clients with JVs, strategic alliances, licenses and collaborations.

Mr. Taft has been recognized as a leading life sciences attorney by numerous legal guides. He has been annually ranked for more than a decade in Chambers USA: America’s Leading Lawyers for Business (Nationwide, Life Sciences: Corporate/Commercial – Band 1). Mr. Taft was inducted into the LMG Life Sciences Hall of Fame, an honor recognizing only a handful of attorneys for their industry contributions.

Before attending Harvard Law School, Mr. Taft earned a B.S in Chemistry from Yale University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Mr. Taft regularly serves as outside general counsel to biotechnology, pharmaceutical, medical device and medtech companies, closely advising management and directors as these companies raise capital, in-license and acquire IP and other assets, and then partner their technology, all with a view towards growth and liquidity.





Representative Matters



Strategic Alliances and M&A
  • SpringWorks Therapeutics in its global clinical collaboration with BeiGene to evaluate combining BeiGene’s investigational RAF dimer inhibitor and SpringWorks Therapeutics’ investigational MEK inhibitor
  • Ambys Medicines in forming a strategic partnership with Takeda and concurrent $140 million funding
  • Wave Life Sciences in its strategic collaboration with Takeda to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system for $110 million upfront and up to $2 billion in milestone payments
  • Aerpio Therapeutics in its global license agreement with Gossamer Bio, with $20 million up-front, potential milestones of up to $400 million, and royalties ranging from a high single digit to mid-teen percentage
  • Alnylam Pharmaceuticals in restructuring its 2013 transformational alliance with Genzyme for RNAi therapeutics as genetic medicines
  • Foundation Medicine in its collaboration agreement and equity transaction with Roche, with total deal value in excess of $1 billion and subsequent merger with Roche valued at $2.4 billion
  • Moderna Therapeutics in numerous strategic transactions with AstraZeneca, Merck and others with upfront deal value in excess of $1 billion in cash and equity, plus downstream payments; most recently, expanded the 2016 Merck deal for novel messenger RNA cancer vaccines
  • Fresenius Medical Care in global partnership with Humacyte to commercialize the investigational human acellular vessel HUMACYL; Fresenius made a $150 million equity investment in Humacyte
  • Warp Drive Bio in its collaboration with Roche on novel classes of antibiotics, valued up to $387 million
  • Dimension Therapeutics in its $151 tender offer and contested sale to Ultragenyx
  • Teva Pharmaceuticals in the sale of its specialty global women’s health business for a combined value of $2.5 billion, including sale of the Paragard® business to CooperSurgical for $1.1 billion, the ex-U.S. women’s health business to CVC Capital Partners for $703 million, and the Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
  • Delinia Therapeutics in its sale to Celgene, valued up to $775 million with up-front payment of $300 million
  • Pieris Pharmaceuticals in its strategic collaboration with AstraZeneca to develop novel inhaled drugs that leverage Pieris’ Anticalin platform, for deal value of up to $2.1 billion
  • Medicxi Ventures as an investor in Impact Biomedicines in connection with its sale to Celgene for up to $7 billion
  • Royalty Pharma in its acquisition from Perrigo Company of royalty rights to Tysabri, for up to $2.8 billion
  • Teva Pharmaceuticals in its global agreement with Regeneron for the phase 3 novel nerve growth factor antibody fasinumab, for $250 million upfront and a share in its global commercial value
  • Pieris Pharmaceuticals in its collaboration with Servier for a dual-checkpoint inhibitor and up to seven other immuno-oncology bispecific drug candidates, for a deal value of up to €1.7 billion
  • Morgan Stanley as financial advisor to Stemcentrx in its sale to AbbVie for $5.8 billion in cash and stock, and up to an additional $4 billion in cash in success-based milestone payments
  • Intellia Therapeutics in its multi-year collaboration with Regeneron on CRISPR/Cas gene-editing technology for in vivo therapeutic development, with $75 million upfront and potential milestone and royalty payments
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, valued up to $600 million with up-front and near-term payments of $225 million 
  • Blueprint Medicines in its collaboration with Roche, up to $1 billion in value with $45 million upfront
  • Surface Oncology in its collaboration with Novartis to develop next generation immunotherapeutics, with Surface to receive up to $170 million in near term cash, plus milestones and royalties
  • Promedior in its option agreement with Bristol-Myers Squibb with potential deal value of up to $1.25 billion
  • Unum Therapeutics in its strategic collaboration with Seattle Genetics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer, with potential deal value of $615 million
  • Teva Pharmaceuticals in its acquisition of Labrys Biologics, for $200 million cash and up to $825 million 
  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • bluebird bio in its global collaboration with Celgene and subsequent update for gene therapies to treat cancer with deal value up to $300 million
Public Offerings
  • Aerpio Therapeutics in its $40 million reverse merger and private placement and subsequent $45 million follow-on offering and up-listing to NASDAQ
  • Scholar Rock in its $86 million initial public offering
  • Surface Oncology in its $108 million initial public offering and concurrent $11.5 million private placement
  • Unum Therapeutics in its $69 million initial public offering and concurrent $5 million private placement
  • Blueprint Medicines in its $147 million initial public offering and subsequent $143, $230 and $350 million follow-on offerings
  • aTyr Pharma in its $75 million initial public offering and $45 million subsequent equity financing
  • Fate Therapeutics in its $40 million IPO, $30 million follow-on offering, and $57 million structured PIPE
  • Ra Pharmaceuticals in its $105 million initial public offering
  • Dimension Therapeutics in its $72 million initial public offering
  • Foundation Medicine in its $106 million initial public offering
Venture Financings
  • Alector Corporation in its most recent $133 million financing and prior $29.5 million financing to advance a broad portfolio of IO programs
  • Kaleido Biosciences in its most recent $101 million financing and prior $85 million financing to develop novel chemistries for the human microbiome
  • Corvidia Therapeutics in its most recent $60 million financing and prior $26 million financing and in-license of a clinical stage asset from AstraZeneca to advance its lead clinical programs in chronic kidney disease 
  • Quentis Therapeutics in its $48 million financing for cancer immunotherapies 
  • Moderna Therapeutics in its most recent $500 million and prior $474 million and $450 equity financings to pioneer mRNA therapeutics
  • Semma Therapeutics in its most recent $114 million financing and prior $44 million financing for stem cell therapies for Type 1 diabetes
  • Arrakis Therapeutics in its $38 million financing to discover a new class of medicines directly targeting RNA
  • Cerevance in its $40 million plus funding and spin-out from Takeda Pharmaceutical for neuroscience
  • Axcella Health in its approximately $80 million financing for amino acid-based products
  • Medicxi Ventures in its approximately $22 million financing of Impact Biomedicines to develop treatments for myeloproliferative neoplasms and other cancers
  • SetPoint Medical in its $100 plus million in financings for its implantable neuromodulation devices
  • Scholar Rock in its $47 million financing and earlier preferred stock financings for therapeutics that target specific growth factors
  • Unum Therapeutics in its $65 million financing for its anti-body directed cellular immunotherapies
  • Surface Oncology in its $35 million financing for cancer immunotherapies
  • Aerpio Therapeutics in its $60 million financings for vascular disease therapies


Mr. Taft has been recognized by numerous legal guides for legal and life sciences industry expertise. In addition to the two listings noted above, Mr. Taft has also been named as a leading business lawyer by U.S. News-Best Lawyers (Biotechnology Law), LMG Life Sciences (Life Sciences Star), The Legal 500 United States (Healthcare: Life Sciences and Venture Capital and Emerging Companies), PLC Cross-border Life Sciences Handbook (Commercial and Partnering), IAM Patent 1000 (Licensing) and The International Who’s Who of Life Sciences Lawyers (Transactional).

Under his leadership, Goodwin’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for four out of the last five years (2013 through 2015, and 2017), LMG Life Sciences’ Venture Capital Law Firm of the Year (2016), and perennial nationwide recognition by Chambers USA.

In The News









J.D., 1997
Harvard Law School

(magna cum laude)

Ph.D., Chemistry, 1993
Massachusetts Institute of Technology
B.S., Chemistry, 1989
Yale University

(magna cum laude)


1997 to 1998 U.S. Court of Appeals for the Federal Circuit, Honorable Raymond C. Clevenger



Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique